Search results for "Patients"

showing 10 items of 962 documents

Increased interleukin-6 and C-reactive protein levels after instrumented lumbar spine fusion in older patients

2019

Purpose: Interleukin 6 (IL-6) and the acute phase C-reactive protein (CRP) blood concentrations after lumbar spine fusion may be affected by age. The purpose of this prospective observational study was to assess postoperative serum levels of pro-inflammatory IL-6 and CRP after instrumented lumbar spine fusion surgery. We hypothesized that older patients would have increased levels of IL-6 and CRP after surgery. Methods: IL-6 and high-sensitive CRP biochemical marker levels were measured before instrumented spinal fusion, and postoperatively at 1 and 3 days, 6 weeks, and 3 months. The 49 patients in this sample were divided into two groups: age ≤ 60 years (n = 23) and age > 60 years (n = 26)…

MalefusionGastroenterologyleikkaushoitoDISEASEsurgery0302 clinical medicinePostoperative Complicationslcsh:Orthopedic surgeryOlder patientsMARKERSMedicinePostoperative PeriodProspective Studieskirurgiata315Aged 80 and over030222 orthopedicsLumbar VertebraebiologyAge FactorsMiddle AgedRECOVERYFemaleSpinal Diseasesmedicine.symptommusculoskeletal diseasesAdultmedicine.medical_specialtyLumbar spine fusionInflammationspinelannerankaC-reactive protein03 medical and health sciencesLumbarAGEselkärankaINFLAMMATIONc-reaktiivinen proteiiniInternal medicineINJURYHumansQUALITYInterleukin 6lumbarAgedbusiness.industryinterleukin-6DISABILITYC-reactive protein030229 sport sciences3126 Surgery anesthesiology intensive care radiologylcsh:RD701-811Spinal Fusionbiology.proteinbusinessBiomarkers
researchProduct

Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multi…

2020

Abstract Aims To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. Methods and results We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility criteria included absence of (i) haemodynamic instability, (ii) right ventricular dysfunction or intracardiac thrombi, and (iii) serious comorbidities. Up to two nights of hospital stay were permitted. Rivaroxaban was given at the approved dose for PE for ≥3 months. The primary outcome was sympto…

Malehome treatmentpulmonary embolismrisk stratification030204 cardiovascular system & hematology0302 clinical medicineRivaroxabanRecurrenceRisk FactorsOutpatientsMedicineProspective StudiesRight ventricular dysfunctionEarly dischargeAged 80 and overeducation.field_of_studyHome treatmentriskinarviointiMiddle AgedEUROPEAN-SOCIETYPatient DischargeINPATIENT TREATMENT3. Good healthPulmonary embolismTreatment OutcomeHOSPITALIZATIONAmbulatoryright ventricular dysfunctionFemaleCardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyAdolescentmanagement trialpotilaan kotiuttaminenkotihoitoPopulationDrug Administration Schedule03 medical and health sciencesYoung AdultInternal medicineMANAGEMENTkliiniset kokeetHumansseurantaddc:610Home treatment; Management trial; Pulmonary embolism; Right ventricular dysfunction; Risk stratification; RivaroxabaneducationRisk stratificationAgedRivaroxabanbusiness.industryManagement trial030229 sport sciences3126 Surgery anesthesiology intensive care radiologymedicine.diseaseInterim analysisOUTPATIENT TREATMENTConfidence intervalhyytymisenestohoitoClinical trialTHROMBOSIS3121 General medicine internal medicine and other clinical medicinelääkehoitosydän- ja verisuonitauditveritulppabusinessPulmonary EmbolismFactor Xa InhibitorsEuropean heart journal
researchProduct

Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus: Findings From the ERA Registry.

2022

RATIONALE AND OBJECTIVE: There is a dearth of data characterizing patients requiring kidney replacement therapy (KRT) for kidney failure due to systemic lupus erythematosus (SLE) and their clinical outcomes. The aim of this study was to describe trends in incidence and prevalence of KRT among these patients as well as to compare their outcomes to patients treated with KRT for diseases other than SLE.STUDY DESIGN: Retrospective cohort study based on kidney registry data.SETTING & PARTICIPANTS: Patients recorded in 14 registries of patients receiving kidney replacement therapy that provided data to the European Renal Association (ERA) Registry between 1992 and 2016.PREDICTOR: SLE as cause…

Malekidney diseasemedicine.medical_treatmentMAINTENANCE DIALYSIS030232 urology & nephrologyLupus nephritislupus nephritis (LN)0302 clinical medicineLupus Erythematosus Systemickidney replacement therapy (KRT)RegistriesRenal InsufficiencyKidney transplantationRISKeducation.field_of_studyKidneyregistry studyIncidence (epidemiology)IncidenceSTAGE RENAL-DISEASELupus Nephritis3. Good healthEuropeRenal Replacement Therapymedicine.anatomical_structureNephrologySURVIVALFemalemedicine.medical_specialtyprevalencePopulationkidney transplantationUNITED-STATESsurvival03 medical and health sciencesAFRICAN-AMERICAN PATIENTSInternal medicinemedicineHumansESRDeducationNEPHRITISDialysisRetrospective Studies030203 arthritis & rheumatologyProportional hazards modelbusiness.industryTRANSPLANTATIONMORTALITYRetrospective cohort studymedicine.diseasekidney failureend-stage renal disease (ESRD)3121 General medicine internal medicine and other clinical medicineSystemic lupus erythematosus (SLE)Kidney Failure ChronicprognosisbusinessAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
researchProduct

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis : 6-year efficac…

2019

Background To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA) Methods Patients who completed the 2-year, open-label, phase III CLinical Study In Pediatric Patients of Etanercept for Treatment of ERA, PsA, and Extended Oligoarthritis (CLIPPER) were allowed to enroll in its 8-year long-term extension (CLIPPER2). Children received ETN at a once-weekly dose of 0.8 mg/kg, up to a maximum dose of 50 mg/week. Efficacy assessments included the JIA core set of outcomes, the JIA American College of Rheumatology response criteria (JIA-ACR), and t…

Malelcsh:Diseases of the musculoskeletal systemArthritisCHILDRENCATEGORIESDISEASE-ACTIVITYEtanerceptEtanerceptEnthesitis-related arthritis (ERA)Juvenile Arthritis Disease Activity ScoreDOUBLE-BLINDINITIATIONNECROSIS-FACTORDEFINING CRITERIAMedicine and Health SciencesMedicineChildNon-U.S. Gov'tClinical trial; Efficacy; Enthesitis-related arthritis; Enthesitis-related arthritis (ERA); Etanercept; Extended oligoarticular juvenile idiopathic arthritis (eoJIA); Juvenile idiopathic arthritis; Psoriatic arthritis (PsA); SafetyOligoarthritisResearch Support Non-U.S. Gov'tMETHOTREXATEClinical trialTreatment OutcomeAntirheumatic AgentsChild PreschoolFemaleSafetymedicine.drugResearch Articlemedicine.medical_specialtyAdolescentEfficacyEnthesitis-related arthritisResearch SupportPsoriatic arthritisPsoriatic arthritis (PsA)Internal medicineAdalimumabJournal ArticleHumansetanercept ; juvenile idiopathic arthritis ; enthesitis-related arthritis ; extended oligoarticular juvenile idiopathic arthritis (eoJIA) ; enthesitis-related arthritis (ERA) ; psoriatic arthritis (PsA) ; efficacy ; safety ; clinical trialPEDIATRIC-PATIENTSbusiness.industryJuvenile idiopathic arthritismedicine.diseaseRheumatologyArthritis JuvenileOligoarticular Juvenile Idiopathic Arthritislcsh:RC925-935Extended oligoarticular juvenile idiopathic arthritis (eoJIA)businessADALIMUMAB
researchProduct

Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

2020

Background: To derive a list of opportunistic infections (OI) through the analysis of the juvenile idiopathic arthritis (JIA) patients in the Pharmachild registry by an independent Safety Adjudication Committee (SAC). Methods: The SAC (3 pediatric rheumatologists and 2 pediatric infectious disease specialists) elaborated and approved by consensus a provisional list of OI for use in JIA. Through a 5 step-procedure, all the severe and serious infections, classified as per MedDRA dictionary and retrieved in the Pharmachild registry, were evaluated by the SAC by answering six questions and adjudicated with the agreement of 3/5 specialists. A final evidence-based list of OI resulted by matching …

Malelcsh:Diseases of the musculoskeletal systemBiologic:Paediatrics: 760 [VDP]Artritis infecciosaMedDRAInfants malaltsArthritisSeverity of Illness IndexHospital patientsCohort StudiesPharmacovigilance0302 clinical medicine030212 general & internal medicineRegistriesChildBiologics; Immunosuppressive therapy; Infections; Juvenile idiopathic arthritis; Opportunisticbiologics ; immunosuppressive therapy ; infections ; juvenile idiopathic arthritis ; opportunisticBarneleddgikt3. Good healthImmunosuppressive therapySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAAntirheumatic AgentsChild PreschoolCohortPediatric Infectious DiseaseFemaleInfectionResearch Articlemedicine.medical_specialtyTuberculosisjuvenil idiopathic arthritisBiologicsOpportunistic InfectionsInfectionsHerpes Zoster03 medical and health sciencesImmunocompromised HostJuvenile idiopathic arthritiInternal medicinePharmacovigilancemedicineHumansTuberculosisbook030203 arthritis & rheumatologyMalalts hospitalitzatsImmunosupressióbusiness.industrySick childrenJuvenile idiopathic arthritismedicine.diseaseRheumatologyArthritis JuvenileInfectious arthritis:Pediatri: 760 [VDP]Orthopedic surgeryOpportunistiske infeksjonerbook.journalOpportunisticlcsh:RC925-935businessInfeccions oportunistesImmunosuppression
researchProduct

Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids

2019

Abstract Objectives We aimed to analyze the prevalence and impact of COPD in older patients hospitalized in internal medicine or geriatric wards, and to investigate adherence to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, associated clinical factors, and outcomes. Design Data were obtained from REgistro POliterapie SIMI (REPOSI), a prospective multicenter observational registry that enrolls inpatients aged ≥65 years. Setting and Participants Older hospitalized patients enrolled from 2008 to 2016 with a diagnosis of COPD. Measures We evaluated adherence to the 2018 GOLD guidelines at admission and discharge, by examining the prescription of inhaled bronchodi…

Malemajor clinical eventmajor clinical eventsPulmonary Disease Chronic Obstructive0302 clinical medicineOlder patientsAdrenal Cortex Hormones80 and over030212 general & internal medicineLS4_4adherenceProspective StudiesGeneral NursingNursing (all)2901 Nursing (miscellaneous)Aged 80 and overCOPDHealth PolicyGeneral MedicineCOPD guidelines adherence major clinical events older patientsolder patientsObstructive lung diseaseBronchodilator Agentsguidelines adherenceHospitalizationInhalationCOPD; guidelines adherence; major clinical events; older patients; Administration Inhalation; Adrenal Cortex Hormones; Aged; Aged 80 and over; Bronchodilator Agents; Female; Humans; Male; Prospective Studies; Pulmonary Disease Chronic Obstructive; Guideline Adherence; HospitalizationAdministrationFemaleGuideline AdherenceCOPD guidelinesCOPD; guidelines adherence; major clinical events; older patients; Nursing (all)2901 Nursing (miscellaneous); Health Policy; Geriatrics and GerontologyChronic Obstructivemedicine.medical_specialtySocio-culturalePulmonary Disease03 medical and health sciencesolder patientInternal medicineAdministration InhalationmedicineHumansCOPDMedical prescriptionAgedPolypharmacybusiness.industrySettore MED/09 - MEDICINA INTERNAOdds ratiomedicine.diseaseConfidence intervalrespiratory tract diseasesCOPD; guidelines adherence; major clinical events; older patientsObservational studyGeriatrics and Gerontologybusiness030217 neurology & neurosurgery
researchProduct

The significance of meaningful and enjoyable activities for nursing home resident’s experiences of dignity.

2016

Background Living in a nursing home may be challenging to the residents’ experience of dignity. Residents’ perception of how their dignity is respected in everyday care is important. Aim To examine how nursing home residents experience dignity through the provision of activities that foster meaning and joy in their daily life. Method A qualitative design was used and 28 individual semistructured interviews conducted with nursing home residents from six nursing homes in Denmark, Norway and Sweden. The data were analysed with qualitative content analysis. Independent ethical committees in all participating countries granted their approval for the study. Findings The participants highlight two…

Malemedia_common.quotation_subjectScandinavian and Nordic Countries03 medical and health sciencesDignity0302 clinical medicineNursingPerceptionMedicineHumans030212 general & internal medicineMeaning (existential)Nurse educationRecreationmedia_commonInpatients030504 nursingbusiness.industryPublic Health Environmental and Occupational HealthPeer reviewNursing HomesHealth promotion:Medisinske Fag: 700::Helsefag: 800::Sykepleievitenskap: 808 [VDP]Female0305 other medical scienceNursing homesbusiness
researchProduct

Impact of atrial fibrillation/flutter on the in-hospital mortality of surgical patients – Results from the German nationwide cohort

2020

To investigate the impact of atrial fibrillation/flutter (AF) on adverse in-hospital outcomes in hospitalized surgical patients.The nationwide German inpatient sample of the years 2005-2018 was used for this analysis. Surgical patients were stratified by AF and compared. Logistic regression models were used to investigate the impact of AF on in-hospital outcomes.In total, 96,589,627 hospitalizations with surgery were included in the present analysis in Germany (2005-2018). Among these, 6,680,261 were additionally coded with AF (6.9%). In-hospital death rate was substantially higher in surgical patients with AF (6.3%) than without (1.1%). Proportion of surgical patients with AF increased fro…

Malemedicine.medical_specialty030204 cardiovascular system & hematologyLogistic regression03 medical and health sciences0302 clinical medicineRisk FactorsGermanyInternal medicineAtrial FibrillationmedicineHumansHospital MortalityRisk factorHeart FailureAtrial fibrillation flutterIn hospital mortalitybusiness.industryMortality rateAtrial fibrillationHematologymedicine.diseaseAtrial Flutter030220 oncology & carcinogenesisCohortFemalebusinessSurgical patientsThrombosis Research
researchProduct

Impact of atrial fibrillation/flutter on the in-hospital mortality of ischemic stroke patients.

2020

Stroke is the second leading cause of death worldwide. Ischemic strokes, which are caused by atrial fibrillation/flutter (AF), may be more devastating than those that occur without AF.The purpose of this study was to investigate the impact of AF on adverse events in hospitalized ischemic stroke patients and to estimate the elevated impact of AF on the occurrence of these adverse events.The nationwide German inpatient sample of the years 2005-2015 was used for this analysis. Ischemic stroke patients were identified by ICD code I63 and stratified by AF. Logistic regression models were used to investigate the impact of AF on adverse in-hospital events and adjusted for age, sex, and comorbiditi…

Malemedicine.medical_specialty030204 cardiovascular system & hematologyLogistic regressionBrain Ischemia03 medical and health sciences0302 clinical medicineRisk FactorsPhysiology (medical)Internal medicineCause of DeathGermanyCase fatality rateAtrial FibrillationmedicineHumanscardiovascular diseases030212 general & internal medicineHospital MortalityAdverse effectStrokeCause of deathAgedRetrospective StudiesAged 80 and overInpatientsAtrial fibrillation flutterbusiness.industryAtrial fibrillationMiddle Agedmedicine.diseasePrognosisSurvival RateAtrial FlutterIschemic strokeCardiologyFemaleCardiology and Cardiovascular MedicinebusinessHeart rhythm
researchProduct

Impact of concomitant deep or superficial venous thrombosis of the legs on survival of patients with pulmonary embolism

2019

Pulmonary embolism (PE) is a frequent cause of death and morbidity. A few studies suggest that clot burden in pulmonary artery bed is related to PE patients' survival, but the impact of concomitant deep venous thrombosis and/or thrombophlebitis (DVT) on short-term survival of PE patients remains unclear. Thus, we aimed to investigate the impact of DVT on adverse outcomes in PE patients.Patients of the nationwide inpatient sample with PE (ICD-code I26) were stratified for DVT (ICD-code I80) and compared for patient characteristics, risk stratification markers, treatments and outcomes. Impact of concomitant DVT on adverse in-hospital outcomes was tested.Overall, 346,586 PE patients (53.3% fem…

Malemedicine.medical_specialty030204 cardiovascular system & hematologyThrombophlebitis03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicine.arterymedicineHumanscardiovascular diseases030212 general & internal medicineCause of deathVenous ThrombosisInpatientsLegbusiness.industryCancermedicine.diseasePulmonary embolismVenous thrombosisConcomitantPulmonary arterySuperficial venous thrombosisFemalePulmonary EmbolismCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct